<code id='94059F9A1E'></code><style id='94059F9A1E'></style>
    • <acronym id='94059F9A1E'></acronym>
      <center id='94059F9A1E'><center id='94059F9A1E'><tfoot id='94059F9A1E'></tfoot></center><abbr id='94059F9A1E'><dir id='94059F9A1E'><tfoot id='94059F9A1E'></tfoot><noframes id='94059F9A1E'>

    • <optgroup id='94059F9A1E'><strike id='94059F9A1E'><sup id='94059F9A1E'></sup></strike><code id='94059F9A1E'></code></optgroup>
        1. <b id='94059F9A1E'><label id='94059F9A1E'><select id='94059F9A1E'><dt id='94059F9A1E'><span id='94059F9A1E'></span></dt></select></label></b><u id='94059F9A1E'></u>
          <i id='94059F9A1E'><strike id='94059F9A1E'><tt id='94059F9A1E'><pre id='94059F9A1E'></pre></tt></strike></i>

          focus

          focus

          author:entertainment    Page View:5819
          Doctor sitting at a crowded desk. -- first opinion coverage from STAT
          Adobe

          SAN FRANCISCO — If you learned anything about nonprofit hospitals on the first day of the J.P. Morgan Healthcare Conference, it’s that they’ve all but abandoned the prospect of making significant profit on patient care. Instead, they’re fully throwing their weight into other ways of making money — things like developing drugs or selling insurance.

          Making money outside of patient care — or “revenue diversification,” if you prefer industry jargon — has always made appearances on hospital slides at the annual investor conference in San Francisco. This year, though, hospital executives are projecting a sense of urgency around growing profit in other areas to make up for losing money on their bread and butter: taking care of patients in hospitals.

          advertisement

          “It used to be nice to have, but now it’s a must-have, especially for not-for-profit health systems,” Niyum Gandhi, the chief financial officer of Boston’s Mass General Brigham said in an interview with STAT after his presentation.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more
          Study suggests Covid rebound is far more common with Paxlovid than without
          Study suggests Covid rebound is far more common with Paxlovid than without

          AdobeAsmallandpreliminarystudypublishedMondayseemstoindicatethatpatientsreceivingthedrugPaxlovidaref

          read more
          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more

          Listen: Biogen's messy board & Laronde's data problem

          SammyKimballforSTATCanunicornssurvivewithoutdata?Didbiotechgetoveritsskis?AndwhatisgoingonatBiogen?W